开能健康(300272) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 405,475,102.35, representing a 6.31% increase compared to CNY 381,392,081.33 in the same period last year[5]. - Net profit attributable to shareholders was CNY 24,810,870.17, up 11.30% from CNY 22,291,406.17 year-on-year[5]. - Basic earnings per share increased by 12.28% to CNY 0.0439 from CNY 0.0391 year-on-year[5]. - Total operating revenue for the current period reached ¥405,475,102.35, an increase of 6.5% compared to ¥381,392,081.33 in the previous period[27]. - Net profit for the current period was ¥33,936,424.65, representing a 15.5% increase from ¥29,349,537.72 in the previous period[28]. - The net profit attributable to the parent company was ¥24,810,870.17, compared to ¥22,291,406.17, marking an increase of 11.3%[29]. - Basic earnings per share rose to ¥0.0439 from ¥0.0391, indicating a growth of 20.3%[29]. Cash Flow - The net cash flow from operating activities increased by 71.33%, reaching CNY 94,400,100.15 compared to CNY 55,098,547.27 in the previous year[5]. - Cash inflow from operating activities totaled ¥455,244,390.92, compared to ¥407,538,441.35 in the previous period, an increase of 11.7%[31]. - The net cash flow from operating activities was $94,400,100.15, an increase of 71.4% compared to $55,098,547.27 in the previous period[32]. - The total cash inflow from investment activities was $190,667,844.80, significantly up from $39,350.50 in the prior period[32]. - The net cash flow from investment activities was $65,195,218.31, recovering from a negative cash flow of -$16,469,475.66 in the previous period[32]. - The total cash inflow from financing activities was $279,906,783.72, slightly down from $289,242,477.08 year-over-year[32]. - The net cash flow from financing activities was $29,041,506.65, improving from a negative cash flow of -$36,861,551.98 in the previous period[32]. - The company reported a total cash outflow from operating activities of $360,844,290.77, compared to $352,439,894.08 in the prior period[32]. - The company’s cash flow from operating activities showed a strong performance despite an increase in cash outflows[32]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,030,683,344.92, a 2.51% increase from CNY 2,956,338,872.28 at the end of the previous year[5]. - The total assets of the company as of March 31, 2025, amounted to CNY 3,030,683,344.92, an increase from CNY 2,956,338,872.28 at the beginning of the period[22]. - Total liabilities increased to ¥1,685,121,305.49 from ¥1,645,242,044.47, reflecting a growth of 2.4%[26]. - The company's total liabilities as of March 31, 2025, were not explicitly stated but can be inferred from the balance sheet[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,018[14]. - The total number of restricted shares at the end of the period was 146,997,457, with no shares released during the current period[18]. - The company completed the transfer of 10,370,000 shares under the 2023 employee stock ownership plan, which has now been fully executed and terminated[20]. - As of March 31, 2025, the company had 2,496,851 convertible bonds remaining, with a total face value of CNY 24,968.51 million, accounting for 99.874% of the total issuance[21]. Inventory and Expenses - Inventory levels rose slightly to CNY 255,906,262.84 from CNY 253,991,509.81, indicating a marginal increase of about 0.8%[25]. - Short-term borrowings increased to CNY 585,476,378.67 from CNY 574,838,290.68, representing a rise of approximately 1.1%[25]. - The company experienced a 154.88% increase in financial expenses, totaling CNY 3,929,498.36, primarily due to a decrease in exchange gains[11]. - Research and development expenses decreased to ¥13,595,783.93 from ¥15,616,827.09, a decline of 12.9%[28]. - The company reported a decrease in financial expenses to ¥3,929,498.36 from ¥1,541,716.48, reflecting a significant increase in interest expenses[28]. Other Information - The company's cash and cash equivalents increased to CNY 789,047,614.73 from CNY 602,535,095.09, reflecting a growth of approximately 30.9%[22]. - The cash and cash equivalents net increase was CNY 188,331,745.49, a 5,059.52% increase from CNY 3,650,181.17 in the previous year[12]. - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[33].